Nick joined DiCE Molecules as the Head of Assay Science in 2018 and is working to leverage chemical evolution in small molecule drug discovery. Prior to DiCE, Nick was a very early scientist at Flexus Biosciences / FLX Bio and helped discover two drugs that are currently in clinical testing for cancer immunotherapy: BMS-986205 in multiple Phase II trials & FLX475 in Phase I. Throughout his career, Nick has been deeply involved in assay development for drug discovery while leading project teams and managing multiple large-scale screening campaigns.
Nick completed his doctoral work at the University of Toronto, studying the molecular structure and mechanism of an enzyme implicated in cancer. He completed a postdoctoral fellowship at Stanford University and aided in the understanding the mechanism of neurotransmission.